



School of Medicine  
University of Missouri-Columbia

**Jamal A. Ibdah, MD, PhD**  
*Professor of Medicine/Gastroenterology*  
*Professor of Medical Pharmacology and Physiology*  
*Raymond E. and Vaona H. Peck Chair in Cancer Research*  
*Director, Division of Gastroenterology and Hepatology*

Five Hospital Drive  
DC043.00, CE405  
Columbia, MO 65212

PHONE: (573) 882-7349  
FAX: (573) 884-4595  
EMAIL: ibdahj@health.missouri.edu

September 25, 2016

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO.:** 29484

**Column:** Review

**Title:** Sirtuins and Nonalcoholic Fatty Liver Disease

**Authors:** Fatiha Nassir and Jamal A. Ibdah

Dear Editor,

Please find enclosed the edited manuscript in Word format.

The manuscript has been revised and formatted according to the guidelines and requirements and all recommended changes by the editors and reviewers were incorporated.

**Response to the Reviewers:**

We thank the reviewers for their valuable comments. Accordingly, we have modified the manuscript and revised the text taking in consideration the reviewers comments and concerns. Below is point-by-point response to the reviewers' comments:

**Reviewer 1 (1047628):** *"It is a well written report/review. Correctly edited and with potential interest. Please, try to expose clearly the knowledge gap and what you propose in this field"*.

Authors' response: We thank the reviewer for his comment. We have revised the "Core Tip" and "Conclusion" to address the reviewer suggestion.

**Reviewer 2 (2631872):**

**Comment 1:** *"clinical and experimental evidence should be clearly displayed, with a table or a figure potential therapeutic options - explored in any subset - should be outlined"*

Authors' response: To address the reviewer suggestion, we have added both a figure (Figure 1) and a table (Table 1) to the revised manuscript. The figure summarizes the most studied sirtuins and NAFLD related findings. The table addresses the development of activators and inhibitors to selectively modulate sirtuins in its early stages to demonstrate potential therapeutic options, as the reviewer suggested.

*Comment 2: "the contribution, if any, of the Authors in this or in related fields of research should be more explicitly stated".*

Authors' response: We have revised the manuscript to briefly address throughout the text the authors' contribution to the field, relevant references were cited.

*Comment 3: this sentence "Recent advances document that sirtuins are implicated in many of the cellular pathways involved in the development and rescue of NAFLD, and hence may represent potential novel targets for treatment of NAFLD" is, seemingly, too generic.*

Authors' response: We have revised the "Core Tip" to address the reviewer concern.

Reviewer 3 (3536702):

*Comment 1: "line 4 on page 8, FAO should be spelled out at the first time of use".*

Authors' response: FAO is spelled out the first time in use in the manuscript as the reviewer suggested.

*Comment 2: "line 7 in the second paragraph on page 9, there is a missing comma between 'the liver' and 'adipose tissue'".*

Authors' response: A comma is added on page 9 of the edited manuscript, to address the reviewer's comment.

Thank you again for considering our manuscript for publication in the *World Journal of Gastroenterology*.

Sincerely yours,



Jamal A. Ibdah

Corresponding Author